Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM 1080

Next Previous
Drug Profile

PM 1080

Alternative Names: HS-20117; HS-20117-2; PM-1080

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotheus
  • Developer Biotheus; Jiangsu Hansoh Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 18 Jun 2026 Efficacy and adverse events data from a phase I trial in Solid tumours released by Jiangsu Hansoh Pharmaceutical
  • 28 May 2025 Phase-II/III clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy) in China (IV) (NCT06417008)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top